Case Study

Supporting an Investment Decision on an Emerging Biotech Acquisition Target

Situation

A large multinational pharmaceutical company engaged HealthQuest Advisors as it considered an investment in an emerging oncology biotech that had recently received approval for its first therapy. The asset had launched in an initial late-line indication, with several additional indications in development, and the client needed an objective view of the therapy’s broader commercial potential. In particular, the client sought to understand the revenue opportunity in the approved indication, the potential upside from movement into earlier lines of therapy as combination regimens advanced, and the market opportunity across additional indications in development.

Approach

HealthQuest Advisors evaluated the competitive landscape across target indications to assess the positioning and differentiation of the therapy within the evolving standard of care. The team conducted interviews with leading clinicians and payer decision-makers to understand clinical adoption drivers, reimbursement dynamics, and perceived value of the therapy. Using a hypothesis-driven framework, HealthQuest developed a value strategy and defined differentiated positioning across key patient segments. The team also modeled market size and five-year revenue potential, incorporating epidemiology, treatment patterns, and expert insights to provide an informed perspective of the market opportunity and investment risks.

Impact

The engagement provided the client with a clear view of the therapy’s opportunity, differentiated positioning, and the principal factors likely to influence investment value across approved and future indications. HealthQuest’s analysis helped clarify the conditions under which the therapy could expand beyond its initial setting and the magnitude of the indication-level opportunity. This provided the client with a stronger foundation for investment committee review, enabling a more confident and well-supported transaction decision.